melanoma: braf/mek-inhibitors as adjuvant therapy
Published 6 years ago • 273 plays • Length 7:23Download video MP4
Download video MP3
Similar videos
-
4:18
braf/mek inhibition as adjuvant treatment in melanoma
-
6:23
adjuvant therapy options in melanoma treatment
-
8:40
melanoma: braf/mek targeted therapy
-
4:14
adjuvant therapy for melanoma: novel treatment options
-
8:47
braf/mek inhibitors in metastatic melanoma
-
4:12
adjuvant therapy in melanoma: combi-ad trial
-
5:37
selecting therapy & managing patients with braf melanoma
-
8:47
adjuvant therapy in melanoma: targeted vs immuno-oncology
-
10:08
emerging approaches for braf-mutant metastatic melanoma
-
5:15
adjuvant therapy for locally advanced melanoma
-
3:20
considerations surrounding adjuvant therapy in melanoma
-
2:10
combined treatment with braf and mek inhibitors in metastatic melanomas with braf mutations
-
1:03
dr. wilson on choosing between braf/mek therapies for patients with melanoma
-
1:33
dr. paul chapman on braf and mek inhibitor combination for advanced melanoma
-
1:08
fda approval of adjuvant dabrafenib/trametinib in braf melanoma
-
5:09
melanoma: braf status and a neoadjuvant therapy approach
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
1:28
jeffrey weber, md, phd: the impact of braf/mek inhibitors in melanoma
-
9:49
melanoma: nuances of braf/mek combinations in the front line